Which medications in the drug class Potassium Channel Blockers are used in the treatment of Multiple Sclerosis?

Updated: Oct 08, 2019
  • Author: Christopher Luzzio, MD; Chief Editor: Jasvinder Chawla, MD, MBA  more...
  • Print

Potassium Channel Blockers

By delaying repolarization and prolonging duration of action potential, agents in this class improve conduction in focally demyelinated axons, which may strengthen skeletal muscle fiber twitch activity and improve peripheral motor neurologic function.

Dalfampridine (Ampyra)

Dalfampridine, a broad-spectrum potassium blocker is approved as a treatment to improve walking in patients with MS. The improvement in walking was demonstrated by an increase in walking speed.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!